Orlando Immunology Center (OIC)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• HIV2 trials

Phase

• Phase 11 trial

Status

• Completed1 trial
• Terminated1 trial

Lead sponsor

• Hookipa Biotech GmbH1 trial
• Theratechnologies1 trial

Closed trials

• Terminated

  Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

  NCT06430905· Phase 1· Hookipa Biotech GmbH· Source

• Completed

  A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

  NCT05388474· Theratechnologies· Source